TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The STAR 3 Study - A Prospective, Randomized, Two-Arm Study to Compare the Efficacy of the MiniMed Paradigm REAL-Time System Versus Multiple Daily Injections (MDI) in Subjects Naïve to Insulin Pump Therapy
Brief Summary: Primary Outcomes: Average decrease in A1c from baseline to end of Study Phase (52 weeks) for subjects in the "722 Group" is greater than that for subjects in the "Control (MDI) Group".

Secondary Outcomes: Incidence and frequency of severe hypoglycemia; Measure of glycemic variability, Area Under the Curve (AUC); Quality of Life; and Health Economic Outcomes (MRU)


Options:
A: Arm Label: A,1; Type: NO_INTERVENTION; Interventions: Device: Real time access to current glucose values during CGMS | Arm Label: A,2; Type: NO_INTERVENTION; Interventions: Device: Real time access to current glucose values during CGMS | Intervention Type: DEVICE; Name: Real time access to current glucose values during CGMS; Assigned to Arm(s): A,1, A,2
B: Arm Label: Standard intensive glucose monitoring; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Continuous Glucose Monitoring (CGM); Type: ACTIVE_COMPARATOR; Interventions: Device: Continuous glucose monitor | Intervention Type: DEVICE; Name: Continuous glucose monitor; Assigned to Arm(s): Continuous Glucose Monitoring (CGM)
C: Arm Label: 722 sensor augmented pump; Type: EXPERIMENTAL; Interventions: Device: MiniMed Paradigm REAL-Time System | Arm Label: Multiple Daily Injections (MDI); Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: MiniMed Paradigm REAL-Time System; Assigned to Arm(s): 722 sensor augmented pump
D: Arm Label: Conventional insulin pump therapy; Type: ACTIVE_COMPARATOR; Interventions: Device: Minimed Paradigm 512/712 Insulin pump | Arm Label: Minimed paradigm Real Time Sytem; Type: EXPERIMENTAL; Interventions: Device: Minimed paradigm Real Time Sytem | Intervention Type: DEVICE; Name: Minimed paradigm Real Time Sytem; Assigned to Arm(s): Minimed paradigm Real Time Sytem | Intervention Type: DEVICE; Name: Minimed Paradigm 512/712 Insulin pump; Assigned to Arm(s): Conventional insulin pump therapy

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An International, Multicenter, Large Simple Trial (LST) To Compare The Cardiovascular Safety Of Ziprasidone And Olanzapine
Brief Summary: The primary objective of the study is to estimate the relative incidence among users of ziprasidone and olanzapine of non-suicide mortality.


Options:
A: Arm Label: A1; Type: EXPERIMENTAL; Interventions: Drug: Ziprasidone | Intervention Type: DRUG; Name: Ziprasidone; Assigned to Arm(s): A1
B: Intervention Type: DRUG; Name: Ziprasidone; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Olanzapine; Assigned to Arm(s): N/A
C: Arm Label: Olanzapine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Olanzapine, Drug: Quetiapine, Drug: Ziprasidone | Arm Label: Quetiapine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Olanzapine, Drug: Risperidone, Drug: Ziprasidone | Arm Label: Risperidone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Olanzapine, Drug: Ziprasidone | Arm Label: Ziprasidone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Olanzapine, Drug: Ziprasidone | Intervention Type: DRUG; Name: Olanzapine; Assigned to Arm(s): Olanzapine, Quetiapine, Risperidone, Ziprasidone | Intervention Type: DRUG; Name: Quetiapine; Assigned to Arm(s): Olanzapine | Intervention Type: DRUG; Name: Risperidone; Assigned to Arm(s): Quetiapine | Intervention Type: DRUG; Name: Ziprasidone; Assigned to Arm(s): Olanzapine, Quetiapine, Risperidone, Ziprasidone
D: Intervention Type: DRUG; Name: perphenazine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: olanzapine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: quetiapine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: risperidone; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: ziprasidone; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: clozapine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: fluphenazine decanoate; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Single-Center, Randomized, Double-Blind, Placebo-Controlled Study of The Efficacy and Safety of Phosphatidylserine-Omega3 in Children With Attention-Deficit/ Hyperactivity Disorder
Brief Summary: The primary objective of this trial is to determine whether an oral administration of Phosphatidylserine-Omega3 would significantly improve the clinical symptoms of children suffering from ADHD. Both the behavior and the academic achievements aspects will be evaluated. In addition, we intend to measure side-effects and adverse events and to examine the possible correlation between biochemical and behavioral alterations.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Phosphatidylserine-Omega3 | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Other: Colored cellulose tainted with fishy odor | Intervention Type: DIETARY_SUPPLEMENT; Name: Phosphatidylserine-Omega3; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: Colored cellulose tainted with fishy odor; Assigned to Arm(s): 2
B: Arm Label: ADHD active; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Eicosapentaenoic acid / Docosahexaenoic acid | Arm Label: ADHD Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo dietary intervention (MUFA) in ADHD group | Arm Label: Active Healthy control; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Eicosapentaenoic acid / Docosahexaenoic acid | Arm Label: Healthy placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo dietary intervention (MUFA) in healthy control group | Intervention Type: DIETARY_SUPPLEMENT; Name: Eicosapentaenoic acid / Docosahexaenoic acid; Assigned to Arm(s): ADHD active | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo dietary intervention (MUFA) in ADHD group; Assigned to Arm(s): ADHD Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Eicosapentaenoic acid / Docosahexaenoic acid; Assigned to Arm(s): Active Healthy control | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo dietary intervention (MUFA) in healthy control group; Assigned to Arm(s): Healthy placebo
C: Intervention Type: DRUG; Name: Phosphatidylserine-Omega3; Assigned to Arm(s): N/A
D: Arm Label: Wheat germ oil; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Wheat germ oil | Arm Label: docosahexaenoic acid; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: docosahexaenoic acid | Intervention Type: DIETARY_SUPPLEMENT; Name: docosahexaenoic acid; Assigned to Arm(s): docosahexaenoic acid | Intervention Type: DIETARY_SUPPLEMENT; Name: Wheat germ oil; Assigned to Arm(s): Wheat germ oil

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: Antenatal corticosteroids result in substantial decrease in neonatal morbidity and mortality by specifically reducing the risk of respiratory distress syndrome, intraventricular hemorrhage and neonatal death among premature infants. No human randomized study has formally compared betamethasone and dexamethasone, the preferred corticosteroids for antenatal therapy, with regards to their effectiveness in reducing neonatal morbidities and mortality. Our objective was to compare betamethasone with dexamethasone in terms of effectiveness in reducing perinatal morbidities and mortality among preterm infants.


Options:
A: Arm Label: Intervention; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Increasing use of Antenatal Corticosteroids (ACS) | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Increasing use of Antenatal Corticosteroids (ACS); Assigned to Arm(s): Intervention
B: Intervention Type: DRUG; Name: Betamethasone(Celestone soluspan) and Dexamethasone; Assigned to Arm(s): N/A
C: Arm Label: 12mg betamethasone+12mg betamethasone; Type: ACTIVE_COMPARATOR; Interventions: Drug: betamethasone 24 mg | Arm Label: 12 mg betamethasone+ placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: 12mg betamethasone +placebo | Intervention Type: DRUG; Name: betamethasone 24 mg; Assigned to Arm(s): 12mg betamethasone+12mg betamethasone | Intervention Type: DRUG; Name: 12mg betamethasone +placebo; Assigned to Arm(s): 12 mg betamethasone+ placebo
D: Arm Label: ACS (Group 1); Type: ACTIVE_COMPARATOR; Interventions: Drug: Betamethason Sodium Phosphate | Arm Label: Placebo (Group 2); Type: PLACEBO_COMPARATOR; Interventions: Drug: Normal saline | Intervention Type: DRUG; Name: Betamethason Sodium Phosphate; Assigned to Arm(s): ACS (Group 1) | Intervention Type: DRUG; Name: Normal saline; Assigned to Arm(s): Placebo (Group 2)

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Combined CABG and Stem-Cell Transplantation for Heart Failure
Brief Summary: This is a prospective double blind trial of intraoperative transmyocardial bone marrow-derived mesenchymal cell transplantation vs placebo in patients with low left ventricular ejection fraction scheduled to coronary bypass operation.


Options:
A: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Coronary bypass operation, Procedure: Bone marrow aspiration (crista iliaca), Biological: Intramyocardial mesenchymal stem cell transplantation | Arm Label: B; Type: PLACEBO_COMPARATOR; Interventions: Procedure: Coronary bypass operation, Procedure: Bone marrow aspiration (crista iliaca), Biological: Intramyocardial injection of autologous serum | Intervention Type: PROCEDURE; Name: Coronary bypass operation; Assigned to Arm(s): A, B | Intervention Type: PROCEDURE; Name: Bone marrow aspiration (crista iliaca); Assigned to Arm(s): A, B | Intervention Type: BIOLOGICAL; Name: Intramyocardial mesenchymal stem cell transplantation; Assigned to Arm(s): A | Intervention Type: BIOLOGICAL; Name: Intramyocardial injection of autologous serum; Assigned to Arm(s): B
B: Arm Label: CD133+ autologous bone marrow stem cells; Type: ACTIVE_COMPARATOR; Interventions: Drug: CD133+ autologous bone marrow stem cell | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: CD133+ autologous bone marrow stem cell; Assigned to Arm(s): CD133+ autologous bone marrow stem cells | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Intervention Type: DRUG; Name: intracoronary infusion of progenitor cells; Assigned to Arm(s): N/A
D: Arm Label: CLBS14: Low-Dose Group; Type: EXPERIMENTAL; Interventions: Biological: CLBS14 (low-dose) | Arm Label: CLBS14: High-Dose Group; Type: EXPERIMENTAL; Interventions: Biological: CLBS14 (high-dose) | Arm Label: Placebo injection; Type: PLACEBO_COMPARATOR; Interventions: Biological: placebo injection | Intervention Type: BIOLOGICAL; Name: CLBS14 (low-dose); Assigned to Arm(s): CLBS14: Low-Dose Group | Intervention Type: BIOLOGICAL; Name: CLBS14 (high-dose); Assigned to Arm(s): CLBS14: High-Dose Group | Intervention Type: BIOLOGICAL; Name: placebo injection; Assigned to Arm(s): Placebo injection

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Control Trial of a Group Therapy Intervention Addressing Body Image and Psychosocial Functioning for Women With Breast Cancer
Brief Summary: The purpose of this study is to test an innovative intervention geared towards issues of identity, body image and sexuality, and to examine the intervention for its impact on body image, quality of life, psychosocial/sexuality/relational functioning.


Options:
A: Intervention Type: BEHAVIORAL; Name: Group Therapy Intervention; Assigned to Arm(s): N/A
B: Arm Label: Group 1- in active treatment; Type: N/A; Interventions: N/A | Arm Label: Group 2 - 2-6 months post-treatment; Type: N/A; Interventions: N/A | Arm Label: Group 3 - 6 mos-3yrs post-treatment; Type: N/A; Interventions: N/A | Arm Label: Group 4 - Palliative treatment; Type: N/A; Interventions: N/A | Arm Label: Group 5 - Referred to dentist/oral team; Type: N/A; Interventions: N/A
C: Arm Label: MBSR self care program including weekly sessions; Type: EXPERIMENTAL; Interventions: Other: MBSR | Arm Label: MBSR self care program; Type: EXPERIMENTAL; Interventions: Other: MBSR | Arm Label: Standard care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: MBSR; Assigned to Arm(s): MBSR self care program, MBSR self care program including weekly sessions
D: Arm Label: Cognitive therapy of depression; Type: EXPERIMENTAL; Interventions: Behavioral: Cognitive therapy of depression | Arm Label: Bright light therapy; Type: EXPERIMENTAL; Interventions: Behavioral: Bright light therapy | Arm Label: Waiting list; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Cognitive therapy of depression; Assigned to Arm(s): Cognitive therapy of depression | Intervention Type: BEHAVIORAL; Name: Bright light therapy; Assigned to Arm(s): Bright light therapy

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomised,Double Blind, Placebo Controlled, Multicentre Trial of Abagovomab Maintenance Therapy in Patients With Epithelial Ovarian Cancer After Complete Response to First Line Chemotherapy
Brief Summary: The purpose of this study is to evaluate the benefit of vaccination with Abagovomab, an experimental immunotherapy in ovarian cancer patients. The benefit will be evaluated in terms of time the remission status is kept as well as prolongation of life expectancy.


Options:
A: Arm Label: 1 Catumaxomab; Type: ACTIVE_COMPARATOR; Interventions: Biological: Catumaxomab (Removab), Procedure: paracentesis | Arm Label: 2:; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BIOLOGICAL; Name: Catumaxomab (Removab); Assigned to Arm(s): 1 Catumaxomab | Intervention Type: PROCEDURE; Name: paracentesis; Assigned to Arm(s): 1 Catumaxomab
B: Arm Label: 0.25ml dose DPX-0907; Type: EXPERIMENTAL; Interventions: Biological: DPX-0907 consists of 7 tumor-specific HLA-A2-restricted peptides, a universal T Helper peptide, a polynucleotide adjuvant, a liposome and Montanide ISA51 VG | Arm Label: 1ml dose DPX-0907; Type: EXPERIMENTAL; Interventions: Biological: DPX-0907 consists of 7 tumor-specific HLA-A2-restricted peptides, a universal T Helper peptide, a polynucleotide adjuvant, a liposome and Montanide ISA51 VG | Intervention Type: BIOLOGICAL; Name: DPX-0907 consists of 7 tumor-specific HLA-A2-restricted peptides, a universal T Helper peptide, a polynucleotide adjuvant, a liposome and Montanide ISA51 VG; Assigned to Arm(s): 0.25ml dose DPX-0907, 1ml dose DPX-0907
C: Intervention Type: BIOLOGICAL; Name: CDX-1401 in combination with Resiquimod and/or Poly-ICLC; Assigned to Arm(s): N/A | Intervention Type: BIOLOGICAL; Name: CDX-1401; Assigned to Arm(s): N/A | Intervention Type: BIOLOGICAL; Name: Resiquimod; Assigned to Arm(s): N/A | Intervention Type: BIOLOGICAL; Name: poly-ICLC; Assigned to Arm(s): N/A
D: Arm Label: Abagovomab; Type: EXPERIMENTAL; Interventions: Biological: Abagovomab | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Intervention Type: BIOLOGICAL; Name: Abagovomab; Assigned to Arm(s): Abagovomab | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multi-center, Open-label, Randomized, Phase 2 Clinical Trial Evaluating Safety and Efficacy of FOLFIRI With Either Panitumumab or Bevacizumab as Second-Line Treatment in Subjects With Metastatic Colorectal Cancer With Wild-type KRAS Tumors
Brief Summary: This is a multi-center, open-label, randomized, phase 2, two-arm clinical trial to be conducted in the United States. Approximately 210 eligible KRAS wild-type expressing metastatic colorectal cancer subjects who have failed first-line oxaliplatin-based chemotherapy (with at least 4 doses of oxaliplatin-based chemotherapy) with at least 4 doses of bevacizumab (failure is defined as toxicity due to oxaliplatin-based chemotherapy or progression of disease on first-line treatment) will be randomized in a 1:1 ratio to receive either a once-every-two-weeks (Q2W) FOLFIRI regimen plus panitumumab 6 mg/kg or a Q2W FOLFIRI regimen plus bevacizumab (either 5 mg/kg or 10 mg/kg, depending on physician choice and institutional standard of care).


Options:
A: Arm Label: bevacizumab alone; Type: ACTIVE_COMPARATOR; Interventions: Drug: bevacizumab | Arm Label: Bevacizumab + erlotinib; Type: EXPERIMENTAL; Interventions: Drug: bevacizumab, erlotinib | Intervention Type: DRUG; Name: bevacizumab; Assigned to Arm(s): bevacizumab alone | Intervention Type: DRUG; Name: bevacizumab, erlotinib; Assigned to Arm(s): Bevacizumab + erlotinib
B: Arm Label: Panitumumab Plus FOLFIRI; Type: EXPERIMENTAL; Interventions: Drug: Panitumumab, Drug: FOLFIRI | Arm Label: FOLFIRI Alone; Type: ACTIVE_COMPARATOR; Interventions: Drug: FOLFIRI | Intervention Type: DRUG; Name: Panitumumab; Assigned to Arm(s): Panitumumab Plus FOLFIRI | Intervention Type: DRUG; Name: FOLFIRI; Assigned to Arm(s): FOLFIRI Alone, Panitumumab Plus FOLFIRI
C: Intervention Type: DRUG; Name: ABX-EGF; Assigned to Arm(s): N/A
D: Arm Label: Arm A; Type: EXPERIMENTAL; Interventions: Drug: Panitumumab, Drug: Leucovorin, Drug: Irinotecan, Drug: 5-Fluorouracil | Arm Label: Arm B; Type: EXPERIMENTAL; Interventions: Drug: Bevacizumab, Drug: Leucovorin, Drug: Irinotecan, Drug: 5-Fluorouracil | Intervention Type: DRUG; Name: Panitumumab; Assigned to Arm(s): Arm A | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): Arm B | Intervention Type: DRUG; Name: Leucovorin; Assigned to Arm(s): Arm A, Arm B | Intervention Type: DRUG; Name: Irinotecan; Assigned to Arm(s): Arm A, Arm B | Intervention Type: DRUG; Name: 5-Fluorouracil; Assigned to Arm(s): Arm A, Arm B

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Trial of Adjunctive Vitamin D in Tuberculosis Treatment
Brief Summary: The purpose of this study is to determine whether vitamin D enhances response to standard antibiotic treatment for pulmonary tuberculosis.


Options:
A: Intervention Type: DRUG; Name: Cholecalciferol; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Migliol Placebo Oil; Assigned to Arm(s): N/A
B: Arm Label: Active Sodium Phenylbutyrate and active cholecalciferol; Type: ACTIVE_COMPARATOR; Interventions: Drug: Active Sodium Phenylbutyrate and active cholecalciferol | Arm Label: Placebo Sodium Phenylbutyrate plus active cholecalciferol; Type: ACTIVE_COMPARATOR; Interventions: Drug: Placebo Sodium Phenylbutyrate plus active cholecalciferol | Arm Label: Active Sodium Phenylbutyrate and placebo cholecalciferol; Type: ACTIVE_COMPARATOR; Interventions: Drug: Active Sodium Phenylbutyrate and placebo cholecalciferol | Arm Label: Placebo Sodium Phenylbutyrate plus placebo cholecalciferol; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo Sodium Phenylbutyrate plus placebo cholecalciferol | Intervention Type: DRUG; Name: Active Sodium Phenylbutyrate and active cholecalciferol; Assigned to Arm(s): Active Sodium Phenylbutyrate and active cholecalciferol | Intervention Type: DRUG; Name: Placebo Sodium Phenylbutyrate plus active cholecalciferol; Assigned to Arm(s): Placebo Sodium Phenylbutyrate plus active cholecalciferol | Intervention Type: DRUG; Name: Active Sodium Phenylbutyrate and placebo cholecalciferol; Assigned to Arm(s): Active Sodium Phenylbutyrate and placebo cholecalciferol | Intervention Type: DRUG; Name: Placebo Sodium Phenylbutyrate plus placebo cholecalciferol; Assigned to Arm(s): Placebo Sodium Phenylbutyrate plus placebo cholecalciferol
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: L-arginine, Drug: Vitamin D | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Vitamin D, Drug: Placebo L-arginine | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: L-arginine, Drug: Placebo Vitamin D | Arm Label: 4; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo L-arginine, Drug: Placebo Vitamin D | Intervention Type: DRUG; Name: L-arginine; Assigned to Arm(s): 1, 3 | Intervention Type: DRUG; Name: Vitamin D; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: Placebo L-arginine; Assigned to Arm(s): 2, 4 | Intervention Type: DRUG; Name: Placebo Vitamin D; Assigned to Arm(s): 3, 4
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Multivitamins; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Multivitamin supplement containing vitamins B, C, and E | Intervention Type: DIETARY_SUPPLEMENT; Name: Multivitamin supplement containing vitamins B, C, and E; Assigned to Arm(s): Multivitamins | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multi-center, Double-blind, Historical Control, Randomized Conversion to Monotherapy Study With Keppra XR for Treatment of Partial Onset Seizures
Brief Summary: The primary objective of this study is to assess the efficacy of two doses of Keppra XR compared with a historical control as the placebo, in the monotherapy treatment of partial onset seizures.


Options:
A: Arm Label: Zonisamide; Type: ACTIVE_COMPARATOR; Interventions: Drug: Zonisamide | Arm Label: Carbamazepine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Carbamazepine | Intervention Type: DRUG; Name: Zonisamide; Assigned to Arm(s): Zonisamide | Intervention Type: DRUG; Name: Carbamazepine; Assigned to Arm(s): Carbamazepine
B: Arm Label: Levetiracetam; Type: EXPERIMENTAL; Interventions: Drug: Levetiracetam | Arm Label: Carabamazepine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Carabamazepine | Intervention Type: DRUG; Name: Levetiracetam; Assigned to Arm(s): Levetiracetam | Intervention Type: DRUG; Name: Carabamazepine; Assigned to Arm(s): Carabamazepine
C: Arm Label: Keppra XR 1000 mg/day; Type: EXPERIMENTAL; Interventions: Drug: Keppra XR | Arm Label: Keppra XR 2000 mg/day; Type: EXPERIMENTAL; Interventions: Drug: Keppra XR | Intervention Type: DRUG; Name: Keppra XR; Assigned to Arm(s): Keppra XR 1000 mg/day | Intervention Type: DRUG; Name: Keppra XR; Assigned to Arm(s): Keppra XR 2000 mg/day
D: Arm Label: lamotrigine 300; Type: EXPERIMENTAL; Interventions: Drug: lamotrigine, 300 mg/day | Arm Label: lamotrigine 250; Type: EXPERIMENTAL; Interventions: Drug: lamotrigine, 250 mg/day | Intervention Type: DRUG; Name: lamotrigine, 300 mg/day; Assigned to Arm(s): lamotrigine 300 | Intervention Type: DRUG; Name: lamotrigine, 250 mg/day; Assigned to Arm(s): lamotrigine 250

Answer: C